ND-021

N/A

Report date: 2024/02/29 20:00:32

Base Information

Drug NameND-021
Drug Alias NameAnti-PDL-1/Anti-4-1BB/Anti-HSA Tri-Specific AntibodyND-021NM21-1480CS-2006CS2006
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibody
Mechanisms of ActionAnti-Programmed death-ligand 1Anti-Tumor necrosis factor receptor superfamily member 9Anti-Serum albumin
TargetsProgrammed death-ligand 1Tumor necrosis factor receptor superfamily member 9Serum albumin
Therapy Area/IndicationsSolid tumoursFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSingaporeTaiwan +[6] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesNumab Therapeutics AgCstone Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesCstone PharmaceuticalsNumab Therapeutics Ag
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasms
Inactive IndicationsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[8] 

Other Information

ATC CodeN/A
Related LinksN/A